|is rgen a biotechnology company||1.18||0.7||5404||14|
RGEN stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, 1832 Asset Management L.P., Bank of New York Mellon Corp, Marshall Wace LLP, Lord Abbett & CO. LLC, Bank of America Corp DE, Marshall Wace North America L.P., and Jennison Associates LLC.What is the target price for Repligen Corp (RGEN)?
RGEN: Raising target price to $310.00 REPLIGEN CORP has an Investment Rating of HOLD; a target price of $310.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.What is Repligen's manufacturing facility?
Repligen retains an exclusive license to intellectual property owned by the University of Michigan in relation to the Orencia product divested to Bristol-Myers Squibb., Facilities. Repligen's company headquarters are housed together with its manufacturing facility in Waltham, Massachusetts.What is the ratio of RGEN to Roe?
Revenue vs Market: RGEN's revenue (17% per year) is forecast to grow faster than the US market (9.7% per year). High Growth Revenue: RGEN's revenue (17% per year) is forecast to grow slower than 20% per year. Future ROE: RGEN's Return on Equity is forecast to be low in 3 years time (9.2%).